World
Century Targets FDA Filing for Diabetes Cell Therapy
By timothy alexander|
1 min read
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) is targeting a fourth-quarter 2026 regulatory filing for its experimental type 1 diabetes cell therapy after reaching general alignment with the U.S. ...